|
Patients (n)
|
20
|
20
| |
|
Age (years)
|
62.3 ± 9.1
|
61.5 ± 10.1
|
0.78
|
|
Female (%)
|
7 (35%)
|
6 (30%)
|
0.74
|
|
Dialysis vintage (years)
|
9.2 ± 4.8
|
6.7 ± 4.5
|
0.11
|
|
Antihypertensive drug users (%)
|
16 (80%)
|
9 (45%)
|
0.02
|
|
Antiplatelet/anticoagulant users (%)a
|
14 (82%)
|
17 (100%)
|
0.23
|
|
Ejection fraction (%)a
|
70.4 ± 5.2
|
60.7 ± 8.0
|
< 0.01
|
|
Comorbidities
|
|
Ischemic heart disease (%)a
|
7 (41%)
|
12 (71%)
|
0.17
|
|
Heart failure (%)a
|
6 (35%)
|
5 (29%)
|
1.00
|
|
Cerebral infarction (%)a
|
3 (18%)
|
2 (12%)
|
1.00
|
|
Cerebral hemorrhage (%)a
|
0 (0%)
|
1 (6%)
|
1.00
|
|
BMI (kg/m2)
|
24.0 ± 5.0
|
24.9 ± 4.3
|
0.57
|
|
White blood cell count (×103/μL)
|
6.3 ± 1.8
|
6.6 ± 2.7
|
0.53
|
|
Hemoglobin (g/dL)
|
11.2 ± 0.8
|
11.0 ± 2.6
|
0.66
|
|
Platelet (×104/μL)
|
20.0 ± 5.2
|
18.5 ± 4.9
|
0.35
|
|
ESA user (%)
|
13 (65%)
|
10 (50%)
|
0.34
|
|
Ferritin (ng/mL)
|
122.4 ± 141.4
|
94.2 ± 53.8
|
0.41
|
|
Phosphate (mg/dL)
|
5.6 ± 1.5
|
5.4 ± 1.6
|
0.72
|
|
Calcium (mg/dL)
|
9.1 ± 0.7
|
8.8 ± 0.6
|
0.20
|
|
Intact PTH (ng/mL)
|
122 ± 98
|
162 ± 163
|
0.34
|
|
Albumin (g/dL)
|
3.5 ± 0.3
|
3.5 ± 0.3
|
0.78
|
|
Total-cholesterol (mg/dL)
|
171 ± 36
|
154 ± 28
|
0.10
|
|
Triglyceride (mg/dL)
|
124 ± 70
|
142 ± 86
|
0.49
|
|
HDL-cholesterol (mg/dL)
|
44 ± 14
|
44 ± 15
|
0.96
|
|
Ankle brachial index (right)
|
1.03 ± 0.25
|
1.09 ± 0.28
|
0.51
|
|
Ankle brachial index (left)
|
1.11 ± 0.19
|
1.12 ± 0.26
|
0.91
|
|
Homocysteine (nmol/mL)
|
35.8 ± 25.1
|
34.7 ± 18.5
|
0.87
|
|
Pentosidine (μg/mL)
|
0.415 ± 0.218
|
0.326 ± 0.108
|
0.11
|
|
hsCRP (mg/dL)
|
0.221 ± 0.174
|
0.187 ± 0.196
|
0.57
|
|
Pentraxin 3 (ng/mL)
|
4.04 ± 1.68
|
4.55 ± 3.76
|
0.58
|
|
Adrenaline (ng/mL)
|
0.02 ± 0.01
|
0.02 ± 0.01
|
0.10
|
|
Noradrenaline(ng/mL)
|
0.33 ± 0.19
|
0.38 ± 0.19
|
0.46
|
|
Dopamine (ng/mL)
|
0.04 ± 0.02
|
0.05 ± 0.02
|
0.13
|
